Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Homologous recombination deficiency
PARP inhibitors
Patient-derived xenografts
Rare cancers
Uterine leiomyosarcoma
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
04 May 2023
04 May 2023
Historique:
received:
14
02
2023
accepted:
25
04
2023
medline:
8
5
2023
pubmed:
5
5
2023
entrez:
4
5
2023
Statut:
epublish
Résumé
Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some individuals benefiting from poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy, which targets this DNA repair defect. In this report, we screened individuals with uLMS, accrued nationally, for mutations in the HR repair pathway and explored new approaches to therapeutic targeting. A cohort of 58 individuals with uLMS were screened for HR Deficiency (HRD) using whole genome sequencing (WGS), whole exome sequencing (WES) or NGS panel testing. Individuals identified to have HRD uLMS were offered PARPi therapy and clinical outcome details collected. Patient-derived xenografts (PDX) were generated for therapeutic targeting. All 13 uLMS samples analysed by WGS had a dominant COSMIC mutational signature 3; 11 of these had high genome-wide loss of heterozygosity (LOH) (> 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic alteration in an HR gene (deletion in BRCA2). A further three samples harboured homozygous HRD alterations (all deletions in BRCA2), detected by WES or panel sequencing, with 5/58 (9%) individuals having HRD uLMS. All five individuals gained access to PARPi therapy. Two of three individuals with mature clinical follow up achieved a complete response or durable partial response (PR) with the subsequent addition of platinum to PARPi upon minor progression during initial PR on PARPi. Corresponding PDX responses were most rapid, complete and sustained with the PARP1-specific PARPi, AZD5305, compared with either olaparib alone or olaparib plus cisplatin, even in a paired sample of a BRCA2-deleted PDX, derived following PARPi therapy in the patient, which had developed PARPi-resistance mutations in PRKDC, encoding DNA-PKcs. Our work demonstrates the value of identifying HRD for therapeutic targeting by PARPi and platinum in individuals with the aggressive rare malignancy, uLMS and suggests that individuals with HRD uLMS should be included in trials of PARP1-specific PARPi.
Sections du résumé
BACKGROUND
BACKGROUND
Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some individuals benefiting from poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy, which targets this DNA repair defect. In this report, we screened individuals with uLMS, accrued nationally, for mutations in the HR repair pathway and explored new approaches to therapeutic targeting.
METHODS
METHODS
A cohort of 58 individuals with uLMS were screened for HR Deficiency (HRD) using whole genome sequencing (WGS), whole exome sequencing (WES) or NGS panel testing. Individuals identified to have HRD uLMS were offered PARPi therapy and clinical outcome details collected. Patient-derived xenografts (PDX) were generated for therapeutic targeting.
RESULTS
RESULTS
All 13 uLMS samples analysed by WGS had a dominant COSMIC mutational signature 3; 11 of these had high genome-wide loss of heterozygosity (LOH) (> 0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic alteration in an HR gene (deletion in BRCA2). A further three samples harboured homozygous HRD alterations (all deletions in BRCA2), detected by WES or panel sequencing, with 5/58 (9%) individuals having HRD uLMS. All five individuals gained access to PARPi therapy. Two of three individuals with mature clinical follow up achieved a complete response or durable partial response (PR) with the subsequent addition of platinum to PARPi upon minor progression during initial PR on PARPi. Corresponding PDX responses were most rapid, complete and sustained with the PARP1-specific PARPi, AZD5305, compared with either olaparib alone or olaparib plus cisplatin, even in a paired sample of a BRCA2-deleted PDX, derived following PARPi therapy in the patient, which had developed PARPi-resistance mutations in PRKDC, encoding DNA-PKcs.
CONCLUSIONS
CONCLUSIONS
Our work demonstrates the value of identifying HRD for therapeutic targeting by PARPi and platinum in individuals with the aggressive rare malignancy, uLMS and suggests that individuals with HRD uLMS should be included in trials of PARP1-specific PARPi.
Identifiants
pubmed: 37143137
doi: 10.1186/s13046-023-02687-0
pii: 10.1186/s13046-023-02687-0
pmc: PMC10157936
doi:
Substances chimiques
AZD5305
0
Platinum
49DFR088MY
Piperazines
0
Poly(ADP-ribose) Polymerases
EC 2.4.2.30
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112Subventions
Organisme : Australian and New Zealand Gynaecological Oncology Group
ID : ACF-07544
Organisme : National Health and Medical Research Council
ID : 1062702
Organisme : Cancer Council Victoria
ID : 1186314
Organisme : Victorian Cancer Agency
ID : CRF10-20
Organisme : Victorian Cancer Agency
ID : CRF16014
Informations de copyright
© 2023. The Author(s).
Références
Gynecol Oncol. 2018 Dec;151(3):562-572
pubmed: 30244960
Clin Cancer Res. 2020 Jul 15;26(14):3881-3888
pubmed: 32299819
PLoS Genet. 2016 Feb 18;12(2):e1005850
pubmed: 26891131
Int J Mol Sci. 2022 Feb 16;23(4):
pubmed: 35216305
Mol Cancer Res. 2021 Aug;19(8):1350-1360
pubmed: 33863812
Genome Biol. 2021 Jul 12;22(1):202
pubmed: 34253237
Cancers (Basel). 2022 Mar 18;14(6):
pubmed: 35326717
Genome Med. 2018 Apr 25;10(1):33
pubmed: 29695279
Nat Rev Cancer. 2019 Sep;19(9):481-482
pubmed: 31263218
Bioinformatics. 2018 Sep 15;34(18):3094-3100
pubmed: 29750242
Nucleic Acids Res. 2016 Sep 19;44(16):e131
pubmed: 27270079
Breast. 2021 Dec;60:26-34
pubmed: 34455227
J Gynecol Oncol. 2020 May;31(3):e21
pubmed: 32266798
Nat Commun. 2020 Nov 4;11(1):5584
pubmed: 33149131
Lancet. 2017 Oct 28;390(10106):1949-1961
pubmed: 28916367
J Clin Invest. 2009 Jan;119(1):91-8
pubmed: 19075392
ESMO Open. 2021 Oct;6(5):100249
pubmed: 34482181
Nucleic Acids Res. 2019 Jan 8;47(D1):D745-D751
pubmed: 30407521
Oncotarget. 2015 May 20;6(14):12234-47
pubmed: 25906748
Int J Gynecol Cancer. 2016 Jul;26(6):1098-104
pubmed: 27177280
Lancet Oncol. 2015 Jan;16(1):87-97
pubmed: 25481791
Nucleic Acids Res. 2021 Jan 8;49(D1):D916-D923
pubmed: 33270111
Int J Hematol Oncol Stem Cell Res. 2015 Jan 1;9(1):1-4
pubmed: 25802693
Anticancer Res. 2014 Feb;34(2):551-6
pubmed: 24510983
Mol Clin Oncol. 2014 Jul;2(4):591-595
pubmed: 24940501
Gynecol Oncol. 2017 Apr;145(1):208-216
pubmed: 28209496
Gynecol Oncol. 2018 Aug;150(2):219-226
pubmed: 29937315
JCO Precis Oncol. 2020 Apr 9;4:
pubmed: 32923896
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
Cancer. 2008 Feb 15;112(4):820-30
pubmed: 18189292
Hum Mutat. 2011 Aug;32(8):894-9
pubmed: 21520341
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
Oncologist. 2019 Jul;24(7):973-979
pubmed: 30541756
Cancer Discov. 2019 Feb;9(2):210-219
pubmed: 30425037
Cancer Res. 2019 Feb 1;79(3):452-460
pubmed: 30530501
Nature. 2019 Nov;575(7781):210-216
pubmed: 31645765
Genome Res. 2017 Dec;27(12):2050-2060
pubmed: 29097403
J Med Chem. 2021 Oct 14;64(19):14498-14512
pubmed: 34570508
Cell Death Differ. 2015 Jul;22(7):1144-57
pubmed: 25501596
Trends Cell Biol. 2016 Jan;26(1):52-64
pubmed: 26437586
Mol Oncol. 2014 Jul;8(5):859-73
pubmed: 24768039
Am J Med Sci. 2018 Oct;356(4):404-407
pubmed: 30041945
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
J Gynecol Oncol. 2014 Oct;25(4):306-12
pubmed: 25142630
Nat Commun. 2018 Sep 28;9(1):3970
pubmed: 30266954
Cancer Res. 2021 Sep 15;81(18):4709-4722
pubmed: 34321239
J Clin Oncol. 1991 Nov;9(11):1962-6
pubmed: 1941054
Am J Clin Oncol. 1986 Feb;9(1):18-20
pubmed: 3953489
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
Nat Biotechnol. 2021 Jul;39(7):885-892
pubmed: 33782612
Gynecol Oncol. 2016 Nov;143(2):379-388
pubmed: 27614696
Cancers (Basel). 2020 Jul 31;12(8):
pubmed: 32751892
Oncotarget. 2017 Jul 4;8(27):44073-44081
pubmed: 28454122
JCO Precis Oncol. 2020 Nov 6;4:
pubmed: 33283135
Nat Rev Clin Oncol. 2011 May;8(5):302-6
pubmed: 21468130
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Nat Genet. 2017 Oct;49(10):1476-1486
pubmed: 28825726
Int J Cancer. 2018 Mar 15;142(6):1230-1243
pubmed: 29063609
Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):
pubmed: 33876771
Ann Oncol. 2014 Aug;25(8):1656-63
pubmed: 24827126
Nat Commun. 2021 Mar 4;12(1):1434
pubmed: 33664264
Lancet Oncol. 2014 Jul;15(8):852-61
pubmed: 24882434
JAMA Oncol. 2023 Jan 1;9(1):29-39
pubmed: 36394867
Gigascience. 2020 Nov 18;9(11):
pubmed: 33205815
Breast Cancer Res. 2008;10(1):R12
pubmed: 18269736
Clin Cancer Res. 2012 Apr 15;18(8):2344-51
pubmed: 22371451
Lancet Oncol. 2017 Sep;18(9):1274-1284
pubmed: 28754483
J Clin Oncol. 2015 Nov 1;33(31):3660-7
pubmed: 26324357
Genome Biol. 2019 Nov 14;20(1):240
pubmed: 31727117
Oncologist. 2015 Apr;20(4):433-9
pubmed: 25765878
Cancer. 2021 Jul 15;127(14):2432-2441
pubmed: 33740262
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3406-11
pubmed: 21300883
Nat Commun. 2018 Jan 10;9(1):144
pubmed: 29321523
Lancet Oncol. 2021 Dec;22(12):1721-1731
pubmed: 34715071
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110
Cancers (Basel). 2020 Jul 14;12(7):
pubmed: 32674439